Literature DB >> 12573625

Quantification of adeno-associated virus particles and empty capsids by optical density measurement.

Jürg M Sommer1, Peter H Smith, Sumathy Parthasarathy, Jesse Isaacs, Sharmila Vijay, Jane Kieran, Sharon K Powell, Alan McClelland, J Fraser Wright.   

Abstract

We show here that UV absorbance of denatured adeno-associated virus (AAV) vector provides a simple, rapid, and direct method for quantifying vector genomes and capsid proteins in solution. We determined the molar extinction coefficients of capsid protein to be 3.72 x 10(6) M(-1) cm(-1) at 260 nm and 6.61 x 10(6) M(-1) cm(-1) at 280 nm. For recombinant AAV vectors, extinction coefficients can be calculated by including the predicted absorbance of the vector DNA. Since the amount of empty capsids in purified vector preparations lowers the A(260)/A(280) ratio in a predictable manner, the vector genome (vg) and capsid particle (cp) titers in purified AAV vector preparations can be calculated from the absorbance at 260 nm and the A(260)/A(280) ratio. To validate this method, the vg and cp titers calculated by UV absorbance were compared with titers determined by quantitative (Q)-PCR and capsid ELISA. The vg titers determined by absorbance agreed well with titers determined by Q-PCR. The cp/vg ratio determined by the A(260)/A(280) method also correlated well with those determined by AAV capsid ELISA in conjunction with Q-PCR. This new method provides a simple and rapid means to determine AAV vg titers and the ratio of empty to full particles in purified virus preparations.

Entities:  

Mesh:

Year:  2003        PMID: 12573625     DOI: 10.1016/s1525-0016(02)00019-9

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  62 in total

1.  Highly divergent integration profile of adeno-associated virus serotype 5 revealed by high-throughput sequencing.

Authors:  Tyler Janovitz; Thiago Oliveira; Michel Sadelain; Erik Falck-Pedersen
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

2.  Proteolytic mapping of the adeno-associated virus capsid.

Authors:  Kim Van Vliet; Veronique Blouin; Mavis Agbandje-McKenna; Richard O Snyder
Journal:  Mol Ther       Date:  2006-09-27       Impact factor: 11.454

Review 3.  Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.

Authors:  Ronald J Mandel; Corinna Burger; Richard O Snyder
Journal:  Exp Neurol       Date:  2007-08-24       Impact factor: 5.330

4.  Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses.

Authors:  Bernd Hauck; Samuel L Murphy; Peter H Smith; Guang Qu; Xingge Liu; Olga Zelenaia; Federico Mingozzi; Jürg M Sommer; Katherine A High; J Fraser Wright
Journal:  Mol Ther       Date:  2008-10-21       Impact factor: 11.454

5.  Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR.

Authors:  Martin Lock; Mauricio R Alvira; Shu-Jen Chen; James M Wilson
Journal:  Hum Gene Ther Methods       Date:  2014-02-14       Impact factor: 2.396

6.  Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties.

Authors:  Alejandra E Arbetman; Michael Lochrie; Shangzhen Zhou; Jennifer Wellman; Ciaran Scallan; Mohammad M Doroudchi; Britta Randlev; Susannah Patarroyo-White; Tongyao Liu; Peter Smith; Howard Lehmkuhl; Lea Ann Hobbs; Glenn F Pierce; Peter Colosi
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

7.  Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial.

Authors:  James A Allay; Susan Sleep; Scott Long; David M Tillman; Rob Clark; Gael Carney; Paolo Fagone; Jenny H McIntosh; Arthur W Nienhuis; Andrew M Davidoff; Amit C Nathwani; John T Gray
Journal:  Hum Gene Ther       Date:  2011-05       Impact factor: 5.695

8.  Quantification of Adeno-Associated Virus with Safe Nucleic Acid Dyes.

Authors:  Jian Xu; Steven H DeVries; Yongling Zhu
Journal:  Hum Gene Ther       Date:  2020-07-14       Impact factor: 5.695

9.  Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.

Authors:  Lindsey A George; Spencer K Sullivan; Adam Giermasz; John E J Rasko; Benjamin J Samelson-Jones; Jonathan Ducore; Adam Cuker; Lisa M Sullivan; Suvankar Majumdar; Jerome Teitel; Catherine E McGuinn; Margaret V Ragni; Alvin Y Luk; Daniel Hui; J Fraser Wright; Yifeng Chen; Yun Liu; Katie Wachtel; Angela Winters; Stefan Tiefenbacher; Valder R Arruda; Johannes C M van der Loo; Olga Zelenaia; Daniel Takefman; Marcus E Carr; Linda B Couto; Xavier M Anguela; Katherine A High
Journal:  N Engl J Med       Date:  2017-12-07       Impact factor: 91.245

10.  Host and vector-dependent effects on the risk of germline transmission of AAV vectors.

Authors:  Patricia Favaro; Harre D Downey; J Shangzhen Zhou; J Fraser Wright; Bernd Hauck; Federico Mingozzi; Katherine A High; Valder R Arruda
Journal:  Mol Ther       Date:  2009-03-17       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.